ValiRx Share News (VAL)

ValiRx Raises GBP950,000 Through Placing To Progress Pipeline (ALLISS)

LONDON (Alliance News) - ValiRx PLC said Friday it has raised GBP950,000 through the issue of 47.5 million shares at 2.00 pence per share.The clinical stage biotechnology company's down

"Major" Milestone As ValiRx's VAL201 Is Granted Patent In EU

LONDON (Alliance News) - Biotechnology company ValiRx PLC said Wednesday its VAL201 compound has been granted a patent in the EU.This, it said, follows a US patent which was granted for a a

ValiRx Posts Positive Results From VAL101 Compound Pre-Clinical Trials

LONDON (Alliance News) - ValiRx PLC on Thursday said pre-clinical studies showed that its VAL101 compund has a potential to prevent cancer growth at cellular biochemical and genomic molecule is is

UPDATE 1-Argentina Merval index to shrink to 28 companies in Q2

BUENOS AIRES, March 28 (Reuters) - Argentina's benchmark Merval stock index will shrink to 28 component companies in the second quarter, down from 31

Argentina Merval index to shrink to 28 companies in Q2

BUENOS AIRES, March 28 (Reuters) - Argentina's benchmark Merval stock index will shrink to 28 component companies in the second quarter, down from 31

ValirX Gets US Patent For Proposed VAL201 Cancer Treatment

LONDON (Alliance News) - Biotechnology firm ValirX PLC said Tuesday its VAL201 therapeutic compound has been granted a patent in the US.VAL201, which is currently in is

YA II CD Lowers ValiRx Interest To Below 3% Threshold (ALLISS)

LONDON (Alliance News) - Life sciences firm ValiRx PLC said on Monday YA II CD Ltd has cut its stake in the company to below 3%.Prior to last Thursday's YA II CD a

ValiRx upbeat on positive VAL201 study results

(ShareCast News) - Clinical stage biotechnology company ValiRx announced positive results in its VAL201 personalised Phase l/II prostate cancer study on Wednesday, adding that with accumulation of safety and tolerability data there is also evidence of disease stabilisation on CT imaging and reductio

ValiRx To Expand VAL201 Studies After Positive Results

ValiRx reports good progress at Georgia drug trial

(ShareCast News) - Life science company focused on clinical stage cancer therapeutic development, ValiRx, updated the market on the clinical development of its novel cancer treatment drug, VAL401. The AIM-traded firm said ValiSeek, the joint venture between ValiRx and Tangent Reprofiling, was formed

ValiRx Interim Loss Widens As It Progresses Drug Pipeline

ValiRx Gets Patent Coverage For VAL401 In New Zealand

ValiRx Issues Shares To Bracknor For Loan Note Conversion (ALLISS)

ValiRx Receives Approval To Submit Application For Cancer Drug Trial

ValiRx Sells TRAC Technology To Germany's Sovicell For EUR800,000